Surgical robots market 2026 explained: 11,710 da Vinci systems, 8,400 surgical robots sold in 2025, and challengers now funded by medtech giants

Intuitive had 11,710 da Vinci surgical systems installed in hospitals worldwide on June 30, 2026, 12% more than a year earlier, the company said in its second-quarter earnings release on July 16. It placed 468 new systems in that quarter, against 395 a year before, and da Vinci procedures grew about 15%. Those three numbers answer most of what readers ask about the size of the surgical robot market. One installed base dominates it, and that base is still growing at double-digit rates.

The wider count comes from the International Federation of Robotics (IFR). In its World Robotics 2026 service robot release on Sept 30, the IFR said 8,400 surgical robots were sold in 2025, up 57%, making surgery the main growth driver of a medical robot segment that reached 15,300 units, up 19%. The IFR cautions that these figures come from a sample of 238 of 1,001 known manufacturers and are not projected to the whole industry. MEKAWIRE uses only such primary statistics, company filings and our own database here, and no market-research estimates of market value.

One company still sets the scale

Intuitive reported 2025 revenue of USD 10.06 billion and 3.153 million da Vinci procedures, and it placed 1,721 da Vinci systems during the year, 870 of them the fifth-generation da Vinci 5. In the second quarter of 2026, revenue rose 19% to USD 2.89 billion, and da Vinci 5 made up 246 of the 468 placements, or 52.6%, by MEKAWIRE calculation, up from 50.6% for 2025 as a whole. The installed base grew by 604 systems in the first half, from 11,106 at the end of 2025.

The business model matters as much as the robot count. Of the 468 systems placed in the second quarter, 254 went out under operating leases and 131 of those under usage-based leases, Intuitive said. Instruments and accessories brought in USD 1.73 billion of the quarter's revenue, far more than the USD 685 million from systems. Each robot is a gateway to recurring sales of instruments, which is why the procedure count, not the unit count, drives the company's guidance of 13.5% to 15.5% da Vinci procedure growth for 2026.

If Intuitive is among the IFR's respondents, its 1,721 placements in 2025 would equal about a fifth of the 8,400 surgical robots the federation counted. The IFR does not name respondents, so that comparison is indicative only. The rest of the count includes orthopaedic, spine, endoluminal and dental systems from a long list of smaller makers.

The challengers are real but still small

Medtronic won US Food and Drug Administration clearance for its Hugo system in urology on Dec 3, 2025, and performed its first US commercial case at Cleveland Clinic on Feb 17, 2026; Hugo is sold in more than 35 countries, the company said. Johnson & Johnson filed its Ottava soft-tissue robot for FDA De Novo review on Jan 7, 2026. In China, Edge Medical listed in Hong Kong in January and reported that it installed or delivered 72 robots in 2025, 50 of them outside China, on revenue up 184.8% to RMB 455.7 million. MicroPort MedBot reported 2025 revenue of RMB 551.1 million, about 73% of it from outside China.

The gap in scale is wide. Intuitive placed 6.5 times as many da Vinci systems in the second quarter of 2026 as Edge Medical delivered in all of 2025, by MEKAWIRE calculation. In Korea, Curexo says on its website that its CUVIS robots have supported more than 35,000 operations worldwide, and it said in September that it had shipped its CUVIS-joint knee robot to Brazil and Paraguay this year.

Why the money comes from medtech incumbents now

The most telling number of the month is not a unit count. Stryker said on Oct 12 that it would invest about USD 400 million in preferred equity in CMR Surgical, the British maker of the Versius robot, and take an exclusive option to buy the whole company. That one investment is 53 times the USD 7.5 million that Aleph Surgical raised in its pre-seed round in September, the only other disclosed surgical-robot venture round in MEKAWIRE's 2026 database. Across all robotics categories, our database holds USD 11,788.8 million of disclosed 2026 funding in 58 disclosed rounds, as of Oct 17.

The pattern runs through the last year. Distalmotion raised USD 150 million in a Series G in November 2025, then took a strategic investment from Johnson & Johnson's venture arm in January. Zimmer Biomet extended its exclusive distribution deal for THINK Surgical's TMINI knee robot on Oct 13. The buyers are the companies that already own hospital sales forces and instrument franchises.